Literature DB >> 18787058

Inhibition of toll-like receptor 2 expression improves insulin sensitivity and signaling in muscle and white adipose tissue of mice fed a high-fat diet.

Andréa M Caricilli1, Paula H Nascimento, José R Pauli, Daniela M L Tsukumo, Lício A Velloso, José B Carvalheira, Mário J A Saad.   

Abstract

The aims of the present study were to investigate the expression of toll-like receptor 2 (TLR2) in muscle and white adipose tissue (WAT) of diet-induced obesity (DIO) mice, and also the effects of its inhibition, with the use of TLR2 antisense oligonucleotide (ASON), on insulin sensitivity and signaling. The expression of TLR2 was increased in muscle and WAT of DIO mice, compared with those that received standard chow. Inhibition of TLR2 in DIO mice, by TLR2 ASON, improved insulin sensitivity and signaling in muscle and WAT. In addition, data show that the inhibition of TLR2 expression prevents the activation of IKBKB, MAPK8, and serine phosphorylation of IRS1 in DIO mice, suggesting that TLR2 is a key modulator of the crosstalk between inflammatory and metabolic pathways. We, therefore, suggest that a selective interference with TLR2 presents an attractive opportunity for the treatment of insulin resistance in obesity and type 2 diabetes.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18787058     DOI: 10.1677/JOE-08-0354

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  59 in total

Review 1.  Mechanisms of inflammatory responses in obese adipose tissue.

Authors:  Shengyi Sun; Yewei Ji; Sander Kersten; Ling Qi
Journal:  Annu Rev Nutr       Date:  2012-03-09       Impact factor: 11.848

Review 2.  Transcriptional control of macrophage polarisation in type 2 diabetes.

Authors:  Karima Drareni; Jean-François Gautier; Nicolas Venteclef; Fawaz Alzaid
Journal:  Semin Immunopathol       Date:  2019-05-02       Impact factor: 9.623

3.  Toll-like receptors regulate B cell cytokine production in patients with diabetes.

Authors:  M Jagannathan; M McDonnell; Y Liang; H Hasturk; J Hetzel; D Rubin; A Kantarci; T E Van Dyke; L M Ganley-Leal; B S Nikolajczyk
Journal:  Diabetologia       Date:  2010-04-11       Impact factor: 10.122

4.  Coactivation of TLR4 and TLR2/6 coordinates an additive augmentation on IL-6 gene transcription via p38MAPK pathway in U937 mononuclear cells.

Authors:  Junfei Jin; Devadoss J Samuvel; Xiaoming Zhang; Yanchun Li; Zhongyang Lu; Maria F Lopes-Virella; Yan Huang
Journal:  Mol Immunol       Date:  2011-10-26       Impact factor: 4.407

Review 5.  Neuroinflammatory basis of metabolic syndrome.

Authors:  Sudarshana Purkayastha; Dongsheng Cai
Journal:  Mol Metab       Date:  2013-10-05       Impact factor: 7.422

6.  Toll-like receptor 2 mediates high-fat diet-induced impairment of vasodilator actions of insulin.

Authors:  Hyun-Ju Jang; Hae-Suk Kim; Daniel H Hwang; Michael J Quon; Jeong-a Kim
Journal:  Am J Physiol Endocrinol Metab       Date:  2013-03-26       Impact factor: 4.310

7.  Potential role of Toll-like receptors in programming of vascular dysfunction.

Authors:  Jennifer A Thompson; R Clinton Webb
Journal:  Clin Sci (Lond)       Date:  2013-03-13       Impact factor: 6.124

Review 8.  The outliers become a stampede as immunometabolism reaches a tipping point.

Authors:  Barbara S Nikolajczyk; Madhumita Jagannathan-Bogdan; Gerald V Denis
Journal:  Immunol Rev       Date:  2012-09       Impact factor: 12.988

Review 9.  Neuroinflammation in overnutrition-induced diseases.

Authors:  Dongsheng Cai
Journal:  Vitam Horm       Date:  2013       Impact factor: 3.421

10.  Increase in plasma endotoxin concentrations and the expression of Toll-like receptors and suppressor of cytokine signaling-3 in mononuclear cells after a high-fat, high-carbohydrate meal: implications for insulin resistance.

Authors:  Husam Ghanim; Sanaa Abuaysheh; Ching Ling Sia; Kelly Korzeniewski; Ajay Chaudhuri; Jose Manuel Fernandez-Real; Paresh Dandona
Journal:  Diabetes Care       Date:  2009-09-15       Impact factor: 17.152

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.